Articles related to OFF-LABEL USE

Testosterone prescribing for women has risen sharply despite the absence of FDA-approved female-specific products. The increase is occurring alongside pharmacy dispensing barriers and renewed regulatory attention, while guideline-supported use remains largely limited to hypoactive sexual desire disorder in postmenopausal women.

Online claims linking GLP-1 receptor agonists to increased penis size continue attracting patient attention. Available evidence suggests perceived changes may reflect weight loss and erectile function changes rather than anatomic growth.

The FDA approved Lytenava as the first ophthalmic bevacizumab formulation for wet AMD. The decision moves bevacizumab beyond repackaged intravenous use, with launch logistics still pending.

Celebrity disclosures about using beta blockers for performance anxiety are prompting patient questions in primary care, reviving a decades-old off-label use with a comparatively lower risk profile than benzodiazepines.

Vitreoretinal surgeons describe off-label fibrin glue application as a localized tamponade alternative for rhegmatogenous retinal detachment repair, hemorrhage control, and retinal edge stabilization in cases where gas or silicone oil poses prohibitive patient or logistical constraints.

Adjunctive low-dose naltrexone did not separate from placebo on depressive symptom reduction in a 38-patient randomized trial of adults with moderate major depressive disorder on existing antidepressants.